Arvinas Doses First Patient in ARV-6723 Phase 1/2 Trial
NEW HAVEN, Conn. — September 28, 2026 Arvinas, Inc. announced that the first participant has been dosed in the...
Phase 1/2
Advertisement
Sarepta to Present Neuromuscular Portfolio Data at NMSG 2026
CAMBRIDGE, Mass. — September 24, 2026 Sarepta Therapeutics, Inc. announced that it will present seven posters covering its neuromuscular...
A2 Biotherapeutics Advances A2B395 in Solid Tumors
AGOURA HILLS, Calif. — September 15, 2026 A2 Biotherapeutics announced encouraging early safety and efficacy findings from the ongoing...
Lyell Immunopharma Completes LYL273 Manufacturing Transfer
SOUTH SAN FRANCISCO, Calif. — September 10, 2026 Lyell Immunopharma, Inc. announced the successful completion of the planned technology...
Opus Genetics Advances OPGx-BEST1 Toward Phase 3
RESEARCH TRIANGLE PARK, N.C. — September 9, 2026 Opus Genetics, Inc. announced positive 3- and 6-month data from the...
Advertisements
CAMP4 Therapeutics Prepares CMP-002 Phase 1/2 Trial for SYNGAP1
WATERTOWN, Mass. — September 8, 2026 CAMP4 Therapeutics Corporation announced plans to host a virtual Analyst Day on September...
Verastem Oncology Advances VS-7375 Across KRAS G12D Cancers
BOSTON, Massachusetts — September 8, 2026 Verastem Oncology announced plans to host an investor event and webcast on October...
Dyne Therapeutics Advances Z-Basivarsen Toward Phase 3 in DM1
WALTHAM, Massachusetts — September 8, 2026 Dyne Therapeutics announced plans to present additional one-year clinical data from the Phase...
Greywolf Therapeutics Advances GRWD0715 Into axSpA Trial
LONDON — September 8, 2026 Greywolf Therapeutics announced that it has dosed the first participants with axial spondyloarthritis (axSpA)...
Mahzi Therapeutics Wins FDA Rare Pediatric Disease Designation
South San Francisco, California, August 25, 2026 Mahzi Therapeutics announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
